WO2014174468A2 - Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (tdah) - Google Patents
Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (tdah) Download PDFInfo
- Publication number
- WO2014174468A2 WO2014174468A2 PCT/IB2014/060952 IB2014060952W WO2014174468A2 WO 2014174468 A2 WO2014174468 A2 WO 2014174468A2 IB 2014060952 W IB2014060952 W IB 2014060952W WO 2014174468 A2 WO2014174468 A2 WO 2014174468A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- zinc
- iron
- fatty acids
- omega
- adhd
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Definitions
- the present invention relates to a composition constituted by the association of omega 3, zinc and iron fatty acids for the treatment of Attention Deficit Hyperactivity Disorder.
- This composition combines three components of a balanced diet essential for neurodevelopment, associating omega 3 fatty acids, zinc and iron for the treatment of Attention Deficit Hyperactivity Disorder, enhancing the action of omega 3 acids as monotherapy, with the addition of zinc and iron, resulting in a synergistic effect of the three active ingredients.
- ADHD Attention Deficit Hyperactivity Disorder
- Colombian Children and Teenagers. Rev. Neurol. 2005; 40 (12): 716-722 ADHD is the most common behavioral problem during childhood, constituting the most frequent chronic disease of school age, representing a complex problem that affects the daily lives of children, and can even be prolonged, in some cases, in life adult
- the prevalence of ADHD ranges, according to the literature, between 1.7% and 17.8% [Ella et al. Treatment of attentlon deficit - hlperactlvlty dlsorder. N. Engl. J. Med 1999] and between 3 and 5% according to the American Psychiatric Association (APA 2001)].
- the diagnosis of ADHD is based on the evaluation of behavior, according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM IV) of the American Psychiatric Association (APA), which is based on the presence of a certain number of symptoms in more than one environment (school, home, etc.) that have manifested from a certain age.
- DSM IV Diagnostic and Statistical Manual of Mental Disorders
- APA American Psychiatric Association
- the evaluation of the responses of the parents and the educators is included, demanding agreement between them about the symptoms and the disturbance generated by them.
- Mltsls EM et al. Parent-teacher concordance for DSM IV attentlon deficit hyperactlvlty dlsorder In a cllnlc referred sample. J. Am. Acad. Chlld Adolesc.
- Psychiatry 2000 39: 308-13].
- the problems associated with ADHD can affect school performance, family, and social relationships, as well as cause cognitive problems and specifically in math, reading and / or language. These children may have misconduct and low self-esteem and half of the patients may have psychiatric problems including anxiety, mood swings and antisocial attitudes such as behavior changes, challenging disorders and even substance abuse problems (illegal drugs) [Blederman J. ADHD across the llfecycle. Blol Psychiatry 1997; 42: 146S]; Blrleson P. et al. The mental health of Young people In Australia: chlld and adolescent component of the natlonal survey. To commentary. Australas Psychiatry.
- the recommended treatment options for ADHD include drug treatment, with psycho-stimulant and non-stimulant medications, and non-drug treatment, within which behavioral therapy is located, among others.
- the treatment for ADHD involves an interdisciplinary intervention, in which doctors, psychologists, psychopedagogues and teachers must intervene.
- Psychoeducational and psychotherapeutic interventions at the individual and family level, and the psychopedagogical approach in children, are the resources in the first instance, within the group of non-pharmacological treatments.
- stimulant drugs such as methylphenidate and dexamphetamine, these being the first-line treatment in ADHD in adults.
- These have demonstrated their effectiveness and safety in various controlled studies, since they have improved, not only the symptoms and deterioration associated with behavior, but also concomitant problems such as low self-esteem, irritability, mood swings, cognitive problems and social and family functioning [Kooij RC et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010; 10: 67].
- atomoxetine sequestive norepinephrine reuptake inhibitor
- atomoxetine selective norepinephrine reuptake inhibitor
- US FDA Food and Drug Administration
- Non-pharmacological treatments for ADHD are: phytotherapics (Pycnogenol ®), homeopathic treatments and nutritional supplements.
- the contribution of a nutritional supplement with essential nutrients for the structure and functioning of the nervous system, which are not covered by the usual diet of children, would be a therapeutic alternative that would report benefits in the improvement of ADHD symptoms and prevent the administration of Psychopharmaceuticals in some cases, while in others it could improve the response to treatment with psychotropic drugs, perhaps meaning the possibility of indicating lower doses of psychoactive drugs in children.
- the present invention relates to an oral pharmaceutical composition
- an oral pharmaceutical composition comprising a therapeutically effective amount of Omega-3 fatty acids, a therapeutically effective amount of Iron and a therapeutically effective amount of Zinc together with pharmaceutically acceptable excipients.
- the composition of this Invention is useful in attention deficit hyperactivity disorder.
- the present invention relates to a process for preparing an oral pharmaceutical composition
- a process for preparing an oral pharmaceutical composition comprising mixing a therapeutically effective amount of Omega-3 fatty acids, a therapeutically effective amount of Iron and a therapeutically effective amount of Zinc, together with excipients. pharmaceutically acceptable.
- the present invention relates to the use of a therapeutically effective amount of Omega-3 fatty acids, combined with a therapeutically effective amount of Iron and a therapeutically effective amount of Zinc in the manufacture of a medicament that is employed in treatment of attention deficit hyperactivity disorder
- Figure 1 is a graph that shows the average residence time for each of the treatment groups studied.
- Figure 2 is a graph showing the average escape latency for each of the treatment groups studied.
- El Hierro modulates the production of dopamine and norepinephrine, through its action as a cofactor in the enzyme limiting the synthesis of monoamines, tyrosine hydroxylase.
- Iron is indispensable for myelination, dendritogenesis and synaptogenesis. Iron deficit in childhood is associated with lower performance in learning, language and reading.
- Zinc is a cofactor of the metabolism of neurotransmitters and fatty acids and regulates the metabolism of dopamine, thus becoming a key mineral for neurotransmission.
- the supply of essential nutrients for the development of brain structure and the development of adequate synaptogenesis can be useful in the performance of higher mental functions, including language, learning, attention and reading in children.
- omega 3 fatty acids Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA) is key since the perinatal period for the development of the central nervous system. DHA has a predominantly structural role, while EPA positively influences brain functioning [Transler C. et al .; The Impact of polyunsaturated fatty aclds in reducing chlld attention deficit and hyperactlvlty dlsorders. ; J Atten Dlsord. 2010 Nov; 14 (3): 232-46. ].
- Iron is an essential mineral for brain development. Iron deficiency states are associated with learning difficulties and decreased attention [Fretham SJ et al .; The role of Iron In learnlng and memory .; Adv Nutr. 2011 Mar; 2 (2): 112-21].
- Zinc deficiency is associated with attention deficit hyperactivity disorder in school-age children [Arnold LE et al .; Zinc In attentlon-def clt / hyperactlvlty dlsorder; J Chlld Adolesc Psychopharmacol. 2005 Aug; 15 (4): 619-21]. Children with low concentrations of zinc in the blood show low levels of free fatty acids, suggesting the existence of alterations in the metabolism of fatty acids as a result of zinc deficiency.
- the present invention relates to an oral pharmaceutical composition used for the disorder of attention deficit hyperactivity disorder comprising a therapeutically effective amount of Omega-3 fatty acids, a therapeutically effective amount of Iron and a therapeutically effective amount of Zinc together with pharmaceutically acceptable excipients
- Omega-3 fatty acids are preferably selected from EPA and DHA and are in a concentration greater than 20 mg / day.
- concentration of Omega-3 fatty acids, in the composition of the present invention is preferably from 500 mg to 1000 mg / day.
- Iron is at a concentration greater than or equal to 1 mg / day and Zinc at a concentration greater than or equal to 1 mg / day.
- the preferred iron concentration in the composition of the present invention is in the range of 1 to 20 mg / day.
- the preferred Zinc concentration in the composition of the present invention is in the range of 1 to 20 mg / day.
- the sources of Iron that can be employed for the purposes of the present invention are: Iron polymaltosate, Ferrous Fumarate, Ferrous Sulfate, Ferrous Gluconate and Ferrous Succinate.
- the source of Iron of the composition of the present invention is Iron polyimaltosate.
- Zinc Sulfate heptahydrate Zinc Oxide, Zinc Sulfate, Zinc Citrate, and Zinc Gluconate.
- the Zinc source of the composition of the present invention is Zinc Sulfate heptahydrate.
- the dosage unit of the composition of the present invention is preferably selected from capsules, powders, or microgranules for oral administration. It could also be administered as food or dietary supplement.
- a process is also described for preparing said composition comprising, mixing a therapeutically effective amount of Omega-3 fatty acids, a therapeutically effective amount of Iron and a therapeutically effective amount of Zinc, together with excipients. pharmaceutically acceptable.
- Each envelope contains:
- Vegetable fish oil is used in Corn Starch, Sugar, Tocopherols and Lecithin, containing at least 12% of polyunsaturated fatty acids (Omega 3). In the mentioned example, (1) contains approximately 698 mg of EPA and 302 mg of DHA.
- Each capsule contains:
- (1) Fish oil containing at least 30% of polyunsaturated fatty acids (Omega 3) is used. In the mentioned example, (1) contains approximately 120 mg of EPA and 80 mg of DHA.
- Polymaltosate iron is used 1- Sift through 1 rom mesh, Tricalcium phosphate, Colloidal silicon dioxide and Microcrystalline cellulose PH101. Pour them into a mixer and mix at 12 rpm for 3 minutes.
- animals in this case, for the study of ADHD, has some advantages over studies that can be carried out in humans. For example, the socioeconomic level, the behavior of parents and the school environment, are often biases that occur in studies with children. Another advantage of animal studies is that the development of subjects in longitudinal studies in children cannot be carried out quickly, so they progress slowly. In animal studies, external intervening variables (interpersonal, social relationships, etc.) can be controlled much more and better, so interpretation of the data is usually easier than in clinical cases. Animal groups can be genetically more homogeneous, more invasive manipulations are allowed to investigate neurochemical or neuropathological alterations and pharmacological treatments and behavioral interventions can be evaluated.
- animal models to be used can be made: genetic models; animals exposed to neurotoxins; other models (Davids et al 2003).
- REHs show several characteristic features of ADHD, which include: A) motor hyperactivity in a novel environment for them; B) high responses in fixed interval extinction programs and C) difficulty in performing operant tasks. These behavioral abnormalities correspond to the clinical features of hyperactivity, impulsivity and learning difficulty, respectively. Similar to what happens with ADHD patients, REHs are more sensitive to immediate behavioral reinforcement and less than a delayed one than control rats (not hypertensive), which supports apparent validity, since children with ADHD generally choose a small but immediate reward, instead of a larger but late one [Reyna C. Animal models of ADHD. Psicol Psicoped Rev Virtual Facul Psicol and Psicopedagog Univ Salvador. 2011, 24 (1), 1-12].
- Zinc micronutrient
- Iron micronutrient
- Atomoxetine at a dose of 1.5 mg / kg.
- mice Male rats of the Wistar-Kyoto strain (spontaneously hypertensive rats) were used, where only female rats of the same species were used in the sexual impulsivity test. In all cases the animals were divided into 3 groups: control group (free of treatments); group treated with the association of nutrients (Q3 + Zn + Fe) and group treated with atomoxetine. Each group consisted of 8 animals and they were not used to repeat the other tests, so the total number of animals was 72 male rats and 12 female rats (the latter free of any treatment for the sexual impulsivity test exclusively ).
- the animals were conditioned for 6 weeks prior to the different tests, kept in watertight compartments individually, with a solid and liquid "ad libitum" diet, a circadian light / dark rhythm of 12 hours. each one, so that all experimental animals were in the same environmental conditions before carrying out the different tests.
- the animals of the control group never received treatment.
- the animals of the group treated with the association of nutrients and the group treated with atomoxetine received two treatments from on the first day of conditioning and for 6 consecutive weeks, twice a day (before lunch and before dinner) for the group treated with the association of nutrients and once a day (before lunch) for the group treated with atomoxetine.
- all the animals were between 12 and 15 weeks old and had a weight range between 245 and 275 g.
- the first two behaviors were considered that the impulsiveness test was negative; in the case of vigorous movements, they were considered positive impulsiveness test.
- the impulsivity test was carried out for one hour per day for three consecutive days.
- Table 1 shows the results observed in the two instances of the Impulsivity Test.
- Table 2 shows the results observed in the two instances of the Sexual Impulsivity Test.
- Table 2 shows that the 8 control rats showed some kind of sexual progress over female rats (both with or without heat). There is a significant reduction, in half, of the number of animals treated with the association of nutrients (Q3 + Zn + Fe) that showed some type of sexual intercourse / attempt on female rats without heat, very close to the group treated with atomoxetine, where only 3 animals had some attempt of sexual approach on females without zeal. In the two active treatment groups, there were no significant changes in intercourse attempts on females in heat.
- a pool of 1.80 m in diameter by 37 cm high, filled with water to a level of 25 cm is used.
- an escape platform composed of a cylinder of 10 cm in diameter of white color was placed, and was located 1 cm below the water so that it was not visible to the animals; different visual space orientators were placed outside the pool at each cardinal point indicating the correct position of the escape route (Morris, 1984).
- Latency of escape time that elapses since the rat is deposited in the water until it manages to locate the escape platform.
- Table 3 shows the average values of each group, in the 2 test instances, obtained for the time of permanence in the correct quadrant.
- Figure 1 shows the average residence time expressed in seconds, for each of the treatment groups studied: Control, (Q3 + Zn + Fe) and Atomoxetine.
- Table 4 describes the values obtained for the escape latency test.
- Figure 2 shows the average escape latency expressed in seconds, for each of the treatment groups studied: Control, (Q3 + Zn + Fe) and Atomoxetine.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112015026764A BR112015026764A2 (pt) | 2013-04-23 | 2014-04-23 | composição de ácidos graxos ômega-3, zinco e ferro para o tratamento do transtorno por déficit de atenção e hiperatividade (tdah) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2013004549A MX362730B (es) | 2013-04-23 | 2013-04-23 | Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (tdah). |
MXMX/A/2013/004549 | 2013-04-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014174468A2 true WO2014174468A2 (es) | 2014-10-30 |
WO2014174468A3 WO2014174468A3 (es) | 2014-12-31 |
Family
ID=51792461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/060952 WO2014174468A2 (es) | 2013-04-23 | 2014-04-23 | Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (tdah) |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR095832A1 (es) |
BR (1) | BR112015026764A2 (es) |
MX (1) | MX362730B (es) |
WO (1) | WO2014174468A2 (es) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704542B2 (en) * | 2001-09-12 | 2010-04-27 | Xanodyne Pharmaceuticals, Inc. | Vitamin/mineral compositions with DHA |
DE202007000949U1 (de) * | 2007-01-23 | 2007-04-12 | Vogel Lukas | Nahrungsergänzungsmittel, bilanzierte Diät oder Arzneimittel für besonders medizinische Zwecke |
-
2013
- 2013-04-23 MX MX2013004549A patent/MX362730B/es active IP Right Grant
-
2014
- 2014-04-09 AR ARP140101549A patent/AR095832A1/es not_active Application Discontinuation
- 2014-04-23 BR BR112015026764A patent/BR112015026764A2/pt not_active Application Discontinuation
- 2014-04-23 WO PCT/IB2014/060952 patent/WO2014174468A2/es active Application Filing
Also Published As
Publication number | Publication date |
---|---|
MX2013004549A (es) | 2014-10-23 |
BR112015026764A2 (pt) | 2017-07-25 |
AR095832A1 (es) | 2015-11-11 |
MX362730B (es) | 2019-02-05 |
WO2014174468A3 (es) | 2014-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hirayama et al. | The effect of phosphatidylserine administration on memory and symptoms of attention‐deficit hyperactivity disorder: A randomised, double‐blind, placebo‐controlled clinical trial | |
Cohen-Silver et al. | Management of infantile colic: a review | |
Morley et al. | Nutrition and cognitive development | |
ES2862914T3 (es) | Métodos, composiciones y dispositivos para satisfacer las necesidades dietéticas de ácidos grasos | |
Esposito et al. | A medical food formulation of Griffonia simplicifolia/magnesium for childhood periodic syndrome therapy: An open-label study on motion sickness | |
CN103533921A (zh) | 用于治疗神经外伤的方法 | |
JP6608858B2 (ja) | 疲労を減少させるためまたは予防するためおよび認知機能を改善するためのl−カルニチン、その塩および誘導体の使用 | |
CN102648749A (zh) | 一种生酮营养粉 | |
EP2627326A2 (en) | Novel omega-3 and omega-6 fatty acid compositions and uses thereof | |
Hayman et al. | Acute vitamin A toxicity: a report of three paediatric cases. | |
Watrobska-Swietlikowska et al. | Evaluation of physical stability of all in one parenteral admixtures for pediatric home care with high electrolytes concentrations | |
ES2832777T3 (es) | Acidos grasos de cadena media y sus triglicéridos para el tratamiento de la ansiedad | |
WO2014174468A2 (es) | Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (tdah) | |
Vasiljev et al. | Overview of iodine intake | |
WO2021255310A1 (es) | Cepa del género bacteroides para su uso en el tratamiento y/o prevención de trastornos alimentarios | |
Mazurek et al. | Dietary supplements use among children from south-eastern Poland | |
CN100512819C (zh) | 无糖维生素口服液 | |
Haskell | Neurodevelopmental Disorders in Children | |
Ross | Fish oil versus cod liver oil: is vitamin D a reason to go back to the future | |
RU2505293C9 (ru) | Способ лечения нарушений нервно-психического развития в детском возрасте | |
Barral et al. | Nutrición y embarazo | |
Farmonova et al. | Calcium Deficiency and Treatment in Children | |
WO2022258873A1 (es) | Combinación nutracéutica y su uso para el tratamiento de trastornos neurológicos | |
Keskin et al. | Protein substitutions as new-generation pharmanutrition approach to managing phenylketonuria | |
Wilson | ADD and ADHD |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015026764 Country of ref document: BR |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14788157 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 112015026764 Country of ref document: BR Kind code of ref document: A2 Effective date: 20151021 |